Building a biopsychosocial model of cancer-related fatigue: the BIOCARE FActory cohort study protocol.
Breast cancer
Cancer-related fatigue
Correlates of fatigue
Fatigability
Follow-up
Structural equation modeling
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Oct 2021
23 Oct 2021
Historique:
received:
12
05
2021
accepted:
04
10
2021
entrez:
24
10
2021
pubmed:
25
10
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Cancer-related fatigue (CRF) is the most common side effect of cancer and cancer treatment. CRF prevalence is up to 50% in breast cancer patients and can continue several years after cancer remission. This persistent subjective sense of exhaustion is multifactorial. Numerous parameters have been evidenced to be related to CRF across biological, physical, psychological, social and/or behavioral dimensions. Although CRF has been studied for many years, the majority of previous studies focused on only one dimension, i.e., physical function. Moreover, few studies investigated CRF longitudinally with repeated measures. These are the two main obstacles that limit the understanding of CRF mechanisms. The purpose of this study is to create a biopsychosocial model of CRF with simultaneous and longitudinal anthropometric, clinical, biological, physical, psychological and sociological parameters. BIOCARE FActory is a multicentric prospective study that will consist of an 18-month follow-up of 200 women diagnosed with breast cancer. Four visits will be scheduled at diagnosis, after treatments, and 12 and 18 months after diagnosis. The same procedure will be followed for each visit. Each session will be composed of anthropometric data collection, a semi-structured interview, cognitive tests, postural control tests, neuromuscular fatigability tests and a cardiorespiratory fitness test. Clinical and biological data will be collected during medical follow-ups. Participants will also complete questionnaires to assess psychological aspects and quality of life and wear an actigraphy device. Using a structural equation modeling analysis (SEM), collected data will build a biopsychosocial model of CRF, including the physiological, biological, psychological, behavioral and social dimensions of CRF. This study aims to highlight the dynamics of CRF and its correlates from diagnosis to post treatment. SEM analysis could examine some relations between potential mechanisms and CRF. Thus, the biopsychosocial model will contribute to a better understanding of CRF and its underlying mechanisms from diagnosis to the aftermaths of cancer and its treatments. This study is registered at ClinicalTrials.gov ( NCT04391543 ), May 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer-related fatigue (CRF) is the most common side effect of cancer and cancer treatment. CRF prevalence is up to 50% in breast cancer patients and can continue several years after cancer remission. This persistent subjective sense of exhaustion is multifactorial. Numerous parameters have been evidenced to be related to CRF across biological, physical, psychological, social and/or behavioral dimensions. Although CRF has been studied for many years, the majority of previous studies focused on only one dimension, i.e., physical function. Moreover, few studies investigated CRF longitudinally with repeated measures. These are the two main obstacles that limit the understanding of CRF mechanisms. The purpose of this study is to create a biopsychosocial model of CRF with simultaneous and longitudinal anthropometric, clinical, biological, physical, psychological and sociological parameters.
METHODS
METHODS
BIOCARE FActory is a multicentric prospective study that will consist of an 18-month follow-up of 200 women diagnosed with breast cancer. Four visits will be scheduled at diagnosis, after treatments, and 12 and 18 months after diagnosis. The same procedure will be followed for each visit. Each session will be composed of anthropometric data collection, a semi-structured interview, cognitive tests, postural control tests, neuromuscular fatigability tests and a cardiorespiratory fitness test. Clinical and biological data will be collected during medical follow-ups. Participants will also complete questionnaires to assess psychological aspects and quality of life and wear an actigraphy device. Using a structural equation modeling analysis (SEM), collected data will build a biopsychosocial model of CRF, including the physiological, biological, psychological, behavioral and social dimensions of CRF.
DISCUSSION
CONCLUSIONS
This study aims to highlight the dynamics of CRF and its correlates from diagnosis to post treatment. SEM analysis could examine some relations between potential mechanisms and CRF. Thus, the biopsychosocial model will contribute to a better understanding of CRF and its underlying mechanisms from diagnosis to the aftermaths of cancer and its treatments.
TRIAL REGISTRATION
BACKGROUND
This study is registered at ClinicalTrials.gov ( NCT04391543 ), May 2020.
Identifiants
pubmed: 34688272
doi: 10.1186/s12885-021-08831-3
pii: 10.1186/s12885-021-08831-3
pmc: PMC8542307
doi:
Banques de données
ClinicalTrials.gov
['NCT04391543']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140Subventions
Organisme : Ligue Contre le Cancer
ID : IP/SC-13605
Informations de copyright
© 2021. The Author(s).
Références
Psychooncology. 2013 May;22(5):1127-33
pubmed: 22692984
Breast Cancer Res Treat. 2007 Oct;105(2):209-19
pubmed: 17203386
Breast Cancer Res Treat. 2008 Nov;112(1):5-13
pubmed: 18064565
Psychooncology. 2018 Jan;27(1):53-60
pubmed: 28075038
J Appl Physiol (1985). 2009 Mar;106(3):975-83
pubmed: 19150854
J Natl Compr Canc Netw. 2010 Aug;8(8):945-53
pubmed: 20870638
BMC Cancer. 2018 Jul 24;18(1):757
pubmed: 30041626
Am J Hosp Palliat Care. 2011 Mar;28(2):119-29
pubmed: 21051784
Springerplus. 2016 Mar 31;5:390
pubmed: 27047716
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):441-6
pubmed: 21831025
Ann Oncol. 2016 Jun;27(6):965-974
pubmed: 26940687
Psychother Psychosom. 2004 May-Jun;73(3):174-82
pubmed: 15031590
J Clin Oncol. 1998 May;16(5):1689-96
pubmed: 9586880
J Neurol Sci. 2016 Aug 15;367:184-202
pubmed: 27423586
J Am Geriatr Soc. 2003 Aug;51(8):1120-4
pubmed: 12890076
Support Care Cancer. 2013 Mar;21(3):873-81
pubmed: 23052910
J Am Coll Cardiol. 2007 Oct 9;50(15):1435-41
pubmed: 17919562
J Clin Oncol. 2000 Feb;18(4):743-53
pubmed: 10673515
J Clin Oncol. 2005 Sep 20;23(27):6613-22
pubmed: 16170168
J Am Med Dir Assoc. 2015 Feb;16(2):173.e17-22
pubmed: 25499428
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Clin Breast Cancer. 2021 Oct;21(5):425-432
pubmed: 33422432
PLoS One. 2013 Dec 31;8(12):e83636
pubmed: 24391800
Eur J Cancer Care (Engl). 2010 Nov;19(6):761-8
pubmed: 19832890
Plast Surg Nurs. 1996 Fall;16(3):131-2
pubmed: 9060751
Oncology. 2018;95(3):188-191
pubmed: 29847828
Multivariate Behav Res. 1990 Apr 1;25(2):173-80
pubmed: 26794479
Support Care Cancer. 2015 Sep;23(9):2779-87
pubmed: 25680766
J Psychiatr Res. 2016 Dec;83:86-93
pubmed: 27580486
Support Care Cancer. 2016 Sep;24(9):3935-42
pubmed: 27116014
Support Care Cancer. 2018 Oct;26(10):3353-3364
pubmed: 29961146
J Physiol. 1954 Mar 29;123(3):553-64
pubmed: 13152698
J Pain Symptom Manage. 2009 Oct;38(4):587-96
pubmed: 19515528
Med Sci Sports Exerc. 2016 Nov;48(11):2320-2334
pubmed: 27031742
J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):177-185
pubmed: 21475694
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Cancer. 2019 Feb 15;125(4):633-641
pubmed: 30561795
Curr Oncol Rep. 2013 Jun;15(3):260-9
pubmed: 23483375
Support Care Cancer. 2019 Jan;27(1):229-238
pubmed: 29936623
Neurophysiol Clin. 2017 Apr;47(2):111-122
pubmed: 28392007
J Affect Disord. 2012 Feb;136(3):895-901
pubmed: 21975139
J Pain Symptom Manage. 2012 Sep;44(3):351-61
pubmed: 22835480
Clin Cancer Res. 2006 May 1;12(9):2759-66
pubmed: 16675568
Ann Oncol. 2004 Jun;15(6):979-86
pubmed: 15151958
Br J Sports Med. 2009 Jun;43(6):392-400
pubmed: 19224911
J Cancer Surviv. 2021 Oct 5;:
pubmed: 34609702
J Pain Symptom Manage. 2017 Dec;54(6):922-928
pubmed: 28807705
Health Qual Life Outcomes. 2016 Jun 07;14:87
pubmed: 27267486
Ann Oncol. 2020 Jun;31(6):713-723
pubmed: 32173483
Support Care Cancer. 2013 Jan;21(1):173-81
pubmed: 22644262
J Physiol. 1969 Oct;204(2):63P-66P
pubmed: 5824654
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Curr Oncol. 2021 Mar 10;28(2):1170-1182
pubmed: 33802111
J Clin Oncol. 2014 Jun 10;32(17):1840-50
pubmed: 24733803
Eur J Cancer. 2012 Mar;48(5):728-36
pubmed: 21752636
Br J Health Psychol. 2009 Feb;14(Pt 1):143-57
pubmed: 18544184
J Natl Compr Canc Netw. 2015 Aug;13(8):1012-39
pubmed: 26285247
Eur J Cancer. 2004 Jan;40(1):43-9
pubmed: 14687788
Ann Oncol. 2000 May;11(5):561-7
pubmed: 10907949
J Clin Exp Neuropsychol. 1988 Oct;10(5):623-39
pubmed: 3066797